| Value | ₹42.00 Cr |
|---|
BSE filing, NSE: MEDICO. Summary written from the filing by ALFA Finder's alert engine.
Medico Remedies Ltd: key numbers
- Share price
- ₹18.65
- Market cap
- ₹154.8 Cr
- Revenue (annual)
- ₹206.4 Cr
- Net profit (annual)
- ₹13.12 Cr
- P/E (TTM)
- 11.2×Sector 48.7×
- Promoter holding
- 61.38%+0.00% QoQ
- FII holding
- 0.60%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Medico Remedies Ltd
All →Medico Remedies Other Announcement
Medico Remedies Ltd has filed its quarterly shareholding pattern statement for the period ended September 30, 2026. This is a periodic regulatory compliance filing.
Medico Remedies Price Movement Clarification
Medico Remedies confirmed to the exchanges that the recent stock price movement is driven by market conditions and no undisclosed information exists.
Medico Remedies Annual General Meeting
Medico Remedies Ltd held its 32nd Annual General Meeting on September 22, 2026, transacting ordinary and special business, including director re-appointments and remuneration revisions.
Medico Remedies Annual Report
Medico Remedies Ltd has submitted its Annual Report for the financial year 2025-26 and the Notice of its 32nd Annual General Meeting.
Medico Remedies Annual General Meeting
Medico Remedies Limited has issued a notice for its 32nd Annual General Meeting scheduled for September 22, 2026. The meeting agenda includes financial statements and director re-appointments.
Medico Remedies Annual General Meeting
Medico Remedies Limited announced its 32nd Annual General Meeting scheduled for September 22, 2026. The meeting will seek shareholder approval for financial statements and various director appointments.
- Value
- ₹0.10 Cr
Other credit rating announcements
All →Bondada Engineering Credit Rating
CRISIL upgraded credit ratings for five subsidiaries of Bondada Engineering to A/Stable or A-/Stable. The upgrade reflects strong financials and supports the group's lender credibility.
20 Microns Credit Rating
CRISIL reaffirmed 20 Microns' bank loan ratings at A/Stable and A1 on ₹117 crore facilities. Ratings remain unchanged from prior assessment.
Epigral Credit Rating
CRISIL revised Epigral's ratings to CRISIL AA/Stable (long-term) and CRISIL A1+ (short-term) on its bank facilities. The action covers Rs.1,050 Crore of rated bank loan facilities.
Mankind Pharma Credit Rating
CRISIL reaffirmed Mankind Pharma's AA+ rating on Rs.2,500 Crore of NCDs and withdrew ratings on Rs.2,500 Crore NCDs and Rs.1,500 Crore commercial paper. The rating action is dated October 29, 2026.
Lloyds Metals & Energy Credit Rating
Crisil Ratings reaffirmed Lloyds Metals' bank facilities at AA/Stable and A1+, with bank limits enhanced to ₹17,112 crore. It assigned AA/Stable to ₹2,400 crore and ₹1,550 crore of NCDs.
Ram Ratna Wires Credit Rating
CARE Ratings assigned and reaffirmed Ram Ratna Wires' bank facility ratings at CARE A-; Positive / CARE A2+ and revised outlook from Stable to Positive. The long-term bank facilities total Rs.1,046.45 Crore, with several facilities enhanced.